Pfizer, Tempus AI, Stryker emerge as AI healthcare productivity plays

The article positions three AI healthcare companies as beneficiaries of a broader shift in investor capital allocation. As global bond yields remain elevated and borrowing becomes more expensive, investors are prioritizing companies that can boost productivity—raising output or quality per dollar spent—rather than those merely cutting costs. This backdrop favors healthcare technology firms that augment medical professionals' speed and accuracy through data and algorithms, a capability all three companies claim.

Pfizer, the largest by market cap at US$152.7b, is the most established but faces structural headwinds: patent expiries, heavy debt, and projected revenue decline. The company is attempting to offset these pressures through AI-powered research and development alongside nearly US$10b in cost savings by 2029, plus a pipeline of new products in oncology, vaccines, and obesity treatment. Its 6.42% dividend yield and below-peer P/E ratio appeal to income-focused investors, yet the dividend is described as "not well covered," signaling dividend safety concerns. Tempus AI, by contrast, operates at much smaller scale (US$9.4b market cap, US$1.4b revenue) but occupies a central position in AI-driven diagnostics and precision medicine. Its "data flywheel"—where each new genomic test feeds back into improving its models—creates a compounding advantage if the business reaches scale. However, it remains unprofitable and carries significant debt alongside high insider compensation and recent insider selling. Stryker, the third player at US$130.1b market cap, sits at the intersection of surgical robotics and hospital digitization, with strong operational metrics including record Mako robotic installations and improving margins. Yet its premium valuation and high debt load suggest expectations are stretched, and execution recovery following a 2026 cyberattack will be critical. Across all three, the article emphasizes that the AI productivity narrative is compelling but incomplete without close attention to balance sheet risks, valuation, and execution quality.